MCA38 Mouse Colon Carcinoma Tumor Growth Study
Objective: Test whether fractionated radiotherapy regimens synergize with anti-CTLA-4 antibody to induce tumor growth inhibition and abscopal effects in the MCA38 mouse colon carcinoma model
This is a MCA38 Mouse Colon Carcinoma Tumor Growth Study protocol using mouse as the model organism. The procedure involves 6 procedural steps, 1 equipment items, 2 materials. Extracted from a 2009 paper published in Clinical Cancer Research.
Model and subjects
mouse • syngeneic mice (MCA38 model) • unknown • Not specified • Not specified
Study window
Estimated timing pending
Core workflow
Tumor cell injection • Tumor palpation and randomization • Treatment group assignment
Primary readouts
- Primary tumor growth/regression
- Secondary tumor growth/regression (abscopal effect)
- Frequency of CD8+ T cells showing tumor-specific IFN-γ production
- Tumor growth inhibition at primary site
Key equipment and reagents
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
- Verify the animal model, intervention setup, and collection timepoints against the source paper.
- Check that every direct vendor link matches the exact specification your lab plans to run.
Use the page like this
- Work through the protocol steps in order and use the inline vendor chips only when you need to source or verify an item.
- Jump to Experimental Context for readouts, data shape, and analysis flow before planning downstream analysis.
Protocol Steps
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Tumor cell injection
MCA38 mouse colon carcinoma cells were injected subcutaneously into syngeneic mice at two separate sites
Note: One site designated as primary (to be irradiated) and one as secondary (outside radiation field)
View evidence from paper
“MCA38 mouse colon carcinoma cells were injected s.c. into syngeneic mice at two separate sites, defined as a primary site that was irradiated, and a secondary site outside the radiotherapy field”
Tumor palpation and randomization
When both tumors became palpable, mice were randomly assigned to 8 treatment groups
Note: Randomization occurred after both tumors were palpable
View evidence from paper
“When both tumors were palpable mice were randomly assigned to 8 groups receiving no radiotherapy or 3 distinct regimens of radiotherapy”
Treatment group assignment
Mice were assigned to 8 groups: control (no treatment), radiotherapy alone (3 regimens), anti-CTLA-4 alone, or combination treatments
Note: Three radiotherapy regimens tested: 20 Gy single dose, 8 Gy × 3 fractions, or 6 Gy × 5 fractions
View evidence from paper
“8 groups receiving no radiotherapy or 3 distinct regimens of radiotherapy (20 Gy × 1, 8 Gy × 3 or 6 Gy × 5 fractions in consecutive days) in combination or not with 9H10 mAb against CTLA-4”
Radiotherapy administration
Primary tumors received radiotherapy according to assigned regimen while secondary tumors remained outside the radiation field
Note: Single dose: 20 Gy × 1; Fractionated: 8 Gy × 3 or 6 Gy × 5 fractions on consecutive days
View evidence from paper
“3 distinct regimens of radiotherapy (20 Gy × 1, 8 Gy × 3 or 6 Gy × 5 fractions in consecutive days)”
Anti-CTLA-4 antibody administration
9H10 monoclonal antibody against CTLA-4 administered to assigned groups in combination with radiotherapy or alone
Note: Timing and dosage of antibody administration not specified
View evidence from paper
“in combination or not with 9H10 mAb against CTLA-4”
Tumor monitoring
Mice were followed for tumor growth and regression at both primary and secondary sites
Note: Both primary (irradiated) and secondary (non-irradiated) tumors were monitored
View evidence from paper
“Mice were followed for tumors growth/regression”